Neurogene (NGNE) Capital Expenditures (2013 - 2026)
Neurogene's (NGNE) quarterly Capital Expenditures came in at $281000.0 in Q1 2026, down 63.97% YoY from $780000.0 in Q1 2025, and up 128.7% on a QoQ basis from -$979000.0 in Q4 2025.
Neurogene (NGNE) Capital Expenditures (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Capital Expenditures data on file, last reported at $281000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 63.97% year-over-year to $281000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$423000.0 (down 130.99% YoY) and the FY2025 annual result came in at $76000.0, down 89.53% from the prior year.
- Capital Expenditures rose to $281000.0 in Q1 2026, from -$979000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.2 million in Q4 2022 to a low of -$979000.0 in Q4 2025.
- A 5-year average of $213764.7 and a median of $141000.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 964.35% — and 2025, when it tumbled 4356.52%.
- Tracing NGNE's Capital Expenditures over 5 years: stood at $1.2 million in 2022, then plunged by 89.54% to $128000.0 in 2023, then sank by 82.03% to $23000.0 in 2024, then plunged by 4356.52% to -$979000.0 in 2025, then surged by 128.7% to $281000.0 in 2026.
- The last three Capital Expenditures figures came in at $281000.0 (Q1 2026), -$979000.0 (Q4 2025), and $127000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 281,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 281,000.00 |
| Jun 30, 2026 | 281,000.00 |
| Mar 31, 2026 | 281,000.00 |
| Mar 31, 2026 | 281,000.00 |
| Dec 31, 2025 | -979,000.00 |
| Dec 31, 2025 | -979,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Sep 30, 2025 | 127,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Jun 30, 2025 | 148,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Jun 30, 2024 | 384,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |